P. Kent Hawryluk has served as Chief Business Officer of Avidity Biosciences LLC, a biotech company focused on antibody-directed oligonucleotide therapeutics, since January 2013. He was also Co-Founder/CEO of MB2 LLC, a clinical-stage company, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Previously, in January 2006, Mr. Hawryluk co-founded Marcadia Biotech, which was acquired by Roche, and served as Chief Business Officer from January 2006 to April 2011. He currently serves as partner of Twilight Venture Partners, LLC, a private seed and early-stage life science venture capital fund and as Board Director of Gemphire Therapeutics (NASDAQ: GEMP). He was a founding partner of JEGI Capital that launched in 2000. Mr. Hawryluk holds a B.A. from Princeton University, an M.B.A. from Kellogg (Northwestern University), and an M.Sc. degree in biology from IUPUI.